Continuous Glucose Monitors (CGMs) prior authorization and benefit limits
Defines prior authorization criteria and member benefit limits (units per period) for multiple CGM systems, list of applicable NDCs/GPIs/MSC products, and system setup limits for receivers, transmitters, sensors, monitors, kits and readers.
No material clinical/coverage changes in this update.
Policy summary
Subject: Continuous Glucose Monitors (CGMs) prior authorization and benefit limits. Status: CURRENT. This policy defines prior authorization criteria and member benefit/unit limits for multiple CGM systems and components (including Dexcom G6/G7, Guardian/Minimed, Simplera Sync, Enlite and related products). It maps applicable NDCs, GPIs and MultiSource Code (MSC) product names (see listed NDCs/GPIs/MSC product names) to the policy limits and summarizes common system setup limits such as 1 receiver / 365 days, 1 transmitter / 365 days (some products 1 transmitter / 90 days), 4 sensors / 28 days or alternate sensor limits (3/30 or 5/30 depending on product), 1 monitor / 365 days, and 1 reader/kit / 365 days. The primary PA criterion: approval if the requested quantity does NOT exceed the program quantity limit or if supporting information is provided for quantities above the limit.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.